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Advances in immunotherapy for the treatment of glioblastoma
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tumours. An up-to-date summary of current Phase I/II and 
ongoing Phase III GBM immunotherapy clinical trials is 
provided in addition to insights into promising preclinical 
approaches which are focused predominantly on increased 
induction of Type 1 helper T cell (Th1) immune responses 
within patients.
Keywords Glioblastoma · Immunotherapy · Brain 
cancer · Vaccines
Introduction
Glioblastoma (GBM), a highly aggressive solid neoplasm 
with an average 5 year survival rate of <5 %, is the most 
lethal form of brain tumour (http://www.braintumourre-
search.org/our-reports). Median survival rates for GBM 
patients have not changed significantly with current stan-
dard of care, involving tumour resection followed by radio-
therapy (RT) with adjunct and concomitant temozolomide 
(TMZ). However this has limited impact, with GBM recur-
rence at distal sites within 7 months [1] with adjunct che-
motherapy being ineffective at stopping tumour progression 
and morbidity. In this regard, novel GBM treatments are 
being investigated including immunotherapy.
Tumour microenvironment
GBM tumours are inherently heterogeneous, each cell type 
contributing towards disease pathogenesis. Although the 
role of stem-like cells has been extensively evaluated, their 
contribution to relapse, chemo- and radio-therapy resistance 
[2] and the role of vascular cells such as microglia, periph-
eral immune and neural processor cells; in the generation of 
Abstract Glioblastoma (GBM) is an aggres ive brain 
tumour, associated with extremely poor prognosis and 
although there have been therapeutic advances, treat-
ment options remain limited. This review focuses n th  
use of immunotherapy, harnessing he p wer of the host’  
immune system to reject cancer cells. Key challenges in 
glioma specific immunotherapy as with many other can-
cers are the limited immunog nicity of the c ncer cells 
and the immunosuppressive environment of the tumour. 
Although specific antigens have been identified in sev-
eral cancers; brain tumours, such as GBM, are considered 
poorly immunogenic. However, as detailed in this review, 
strategies aimed at circumventing these challenges are 
showing promise for GBM treatment; including identifica-
tion of glioma specific antigens and endogenous immune 
cell activation in an attempt to ove come he imm n-
suppressive environment which is associated with GBM 
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promotion of M1-microglia activation within GBM tumours 
represents an opportunity to enhance an anti-glioma effect.
Immunotherapy
The immune system plays a vital role in the formation 
and establishment of tumours, having host-protective 
and tumour-promoting functions. This immune process 
is described as ‘cancer immunoediting’ or the ‘th ee E′s’ 
[14]. ‘Elimination’, when transformed cells are successfully 
destroyed by a competent immune system. However, tumour 
cells can survive immune destruction and may enter a subse-
quent phase called ‘Equilibrium’; whereby immunoediting 
occurs through cell-associated antigen mutation, downregu-
lation, deletion and/or selective survival of certain antigen 
negative or positive subpopulations, involving downregula-
tion of major histocompatibility complex (MHC)—class II, 
increased expression of cytotoxic T lymphocyte-associated 
protein 4 (CTLA-4), programed cell death protein (PD-1), 
IL-10 and TGF-β, in addition to recruitment of regulatory T 
cells to dampen the immune response [15 , 16]. This phase 
presents a major challenge to immunotherapy. ‘Escape’, is 
when immunologically edited tumours grow and present 
in a clinical setting, establishing an immunosuppressive 
tumour microenvironment where tumour infiltrating lym-
phocyte (TIL) activity is supressed.
Immunotherapeutic approaches can be categorised as 
active or passive, further summarised into several differ-
ent strategies (Fig. 1 ). Pa sive immunotherapy involves 
the direct transfer of effector immune cells into patients 
to induce an anti-tumour effect; such effector cells include 
NK and lymphokine-activated killer (LAK) cells, but may 
also involve the use of antibodies or targeted toxins. Active 
immunotherapy aims at promoting activation of a Th1 
immune response through tumour vaccines, non-specific 
immune stimulants, or cellular vaccines such as dendritic 
cell or tumour cell vaccines. In the following sections, we 
will review current research of GBM immunotherapies 
including the use of checkpoint inhibitors, adoptive cell 
therapy, immunovirotherapy, dendritic-cell-based therapy, 
and peptide vaccination.
Checkpoint inhibitors The immune system is heavily reli-
ant upon multiple checkpoints to avoid the attack of healthy 
cells. Immune checkpoint proteins are surface and secreted 
molecules that inhibit over-activation, an aspect tumour 
cells often take advantage of in order to avoid detection. 
Checkpoint inhibitors target molecules serving as checks 
on the immune response, enhancing pre-existing anti-can-
cer immune responses. CTLA-4 and PD-1 with their cor-
responding ligands (CD80/CD86, PD-L1 and PD-L2) are 
the most extensively studied immune checkpoint proteins 
in cancer [17 ]. CTLA-4 targeting is currently in Phase 
a specific niche within which GBM cells can evade immune 
detection is a topic of ongoing arch. A detailed under-
standing of the supportive role that the microenvironment 
plays in GBM is critical to the design of effective immuno-
therapeutic strategies. Glioma histology shows that >30 % 
of GBM tumours are composed of infiltrating microglia [3] 
with active recruitment of peripheral macrophages [4]; or 
the purpose of this review we hav  focused on the contribu-
tion which microglia play in GBM immune evasion.
The secretion of immunomodulatory cytokines from 
GBM cells, including interleukins 10 (IL-10), 4 (IL-4) and 
6 (IL-6), and particularly, tumour g wth factor-beta (TGF-
β) in addition to prostaglandin E2 [5] can supress microg-
lia activation [6]. Th s, in combination wi h red ced vels 
of major histocompatibility omplex (MHC)II expression 
on GBM microglia significantly contributes to immune 
evasion. Microglia have been show to increase GBM cell 
migration and invasion through interaction with mem-
brane type I metalloproteinases (MMPs) and s cretion of 
matrix-degrading enzymes [7]. Inhibition of TGF-β/Smads 
signalling restores immune surveillance in gli ma models 
[8] inhibiting proliferation through plat let-derived growth 
factor-β (PDGF-β) and microRNA-182. Additionally, inva-
siveness is inhibited via microRNA-182 and -10 and matrix 
metalloproteinases (MMP), with angiogenesi  inhibition 
via vascular endothelial growth factor (VEGF), Insu i -like 
growth factor-binding protein 7 (IGFBP7), and c-Jun N-ter-
minal kinases (JNK). Inhibition of the TGF-β/Smads sig-
nalling pathway restores immunosurveillance by ac ivating 
natural killer (NK) cells, cytotoxic T lymphocytes (CTL) 
and dendritic cells (DC), and by downregulating T regu-
latory (Treg) cells. TGF-β inhibition also reduces glioma 
stem-like cell (GSC) stemness via Leukaemia inhibitory 
factor (LIF), Sox4-Sox2, and inhibitor of DNA binding 1–3 
(Id1–Id3) [9]. Notably, in clinical trials, toxicity is signifi-
cant (reviewed by Han et al. [9]) however a Phase IIb trial 
using TGF-β antisense (Trabedersen) showed promise [10] 
but further studies have not progressed to date.
Although oversimplification, macrophage, or microg-
lia, activation can be categorised as M1-activation which 
is promoted by interferon gamma nd contributes to Th1
responses and M2-activation which can be promoted by 
IL-4 and IL-13 [11 ]. In 2016, Szulzewsky et al. profiled 
GBM tumour-associated microglia (GAMs) identifying 
expression of both M1 and M2 associated genes, de en-
dent on cell origin [12 ]. They identified pro-tumourigenic 
Osteoactivin (GPNMB) and Osteopontin (SP1) expression, 
supporting the role which microglia play in GBM tumour 
progression. Disruption of CD47-SIRPα axis using mono-
clonal antibodies resulted in enha ced phagocytosis of 
glioma cells [13 ] and enhanced activation of both M1 and 
M2 macrophage subtypes with significant shift towards 
the M1 (anti-tumourigenic) phe otype This indicates that 
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antibodies; Durvalumab (MED14736; NCT02336165) and 
Pembrolizumab (Keytruda®; NCT02337491) are currently 
underway in primary GBM patients. A randomised Phase 
III trial testing intravenous administration of Nivolumab 
(Opdivo®; NCT02017717), an anti-PD-1 antibody, in recur-
rent GBM patients, alone and in combination with Bevaci-
zumab or the anti-CTLA-4 drug Ipilimumab (Yervoy®), is 
due for completion in 2018.
Adoptive cell therapy (ACT) is personalised immu-
notherapy where anti-tumour lymphocytes or peripheral 
blood mononuclear cells (PBMC) are expanded ex vivo and 
selected for efficient recognition of tumour associated anti-
gens (TAAs). Specific TAAs can be undetectable or mod-
estly expressed on surrounding healthy tissue, therefore 
serving as an attractive target for immunotherapy. ACT can 
exploit host cells which exhibit anti-tumour reactivity such 
as NK, LAKs and gamma-delta (γδ) T cells whose expan-
sion and activation favours an anti-tumour effect [23 , 24]. 
III trials of recurrent GBM usi g Ipil mumab (Yervoy®; 
NCT02017717). Researchers have also assessed the ben-
eficial therapeutic response to anti-PD-1 immunotherapy in 
several forms of cancer [18 ]. Initial studies have found that, 
with respect to mutational loa , the greater the number of 
mutations present within the tumour genome, the gr ter the 
patient response to anti-PD-1 i munotherapy [19]. Based 
on a metastatic melanoma stu y by Hugo et al. [20], a tenu-
ation of the innate anti-PD-1 res stance (IPRES) transcrip-
tional signature may help improve translatio al anti-PD-1 
responses in cancer; although resistance mechanism  to this 
form of treatment have also b n investigated [21 ]. This 
finding provides substantial hope for anti-PD-1 treatment 
in GBM which is characterised by high somatic mutations. 
Notably, PD-L1 expression was found to be prevalen  in 
GBM and brain metastases, with GBM sh wing high PD-L1 
positivity; providing promise for the use of PD-L1 inhibi-
tors [22 ]. Phase II clinical trials involving two a ti-PD-1 
Fig. 1 Glioblastoma immunotherapy approaches. Immunotherapy 
is the process by which the host immune system is modulated in an 
attempt to generate a tumour-targeted response. These techniques, as 
outlined in the graphical summary above, include adoptive cell ther-
apy (ACT) whereby the host immune system is stimulated to elicit 
a response, immunovirotherapy which involves the use of oncolytic 
viruses which are only capable of replication within cancer cells with 
subsequent cell lysis. Peptide vaccinations are developed through 
either tumour isolated, or synthesised, peptide fragment which, when 
combined with carrier protein adjuvants, are then used to vaccinate the 
host against a particular antigen; and finally dendritic ell-based ther-
apy whereby tumour specific antigens (TSA) and tumour associated 
antigen (TAAs) are used to direct a dendritic cell-prompted immune 
respo se. S veral of these techn ques have entered Phase III clinical 
trials with respect to glioblastoma treatment
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for antigens that, once expressed in the infected cells, elicit 
an immune response. Typically, viruses are immunogenic 
and can be engineered to express specific tumor antigen 
transcripts, resulting in an enhanced presentation of tumor 
antigens to the immune system. This leads to an increase in 
cytotoxic T lymphocytes targeting tumor cells expressing the 
tumor antigen encoded in the vaccine vector [34]. In addition, 
viruses have also been used as oncolytic agents (oncolytic 
virotherapy). Oncolytic viruses cannot undergo replication 
except in specific tumour cells, reducing off-target effects, 
supported through the use of specific surface markers [35]. 
Several viruses, including adenovirus, measles and herpes 
simplex, have been clinically tested as oncolytic agents [36]; 
however genetically-engineered adenoviruses were the first 
to enter clinical trials. GBM Phase I clinical trials using viro-
therapy include modified measles virus producing carcino-
embryonic antigen (CEA; NCT00390299) and genetically 
engineered poliovirus PVS-RIPO (NCT01491893) recognis-
ing Necl-5, a GBM tumour antigen cell adhesion molecule 
[37]. GBM selective adenovirus Delta-24-RGD (DNX-
2401) can infect, replicate within and destroy glioma cells 
[38 ]. Based on these promising results, researchers began a 
first-in-human Phase I study (NCT02197169) to assess viral 
capacity to replicate in gliomas. Preliminary viral immuno-
therapy studies use direct intratumoural administration [39,
40]; therefore efficacy of systemic administration and anti-
tumour effect has yet to be assessed.
Peptide vaccination concerns generation of vaccines 
based on peptide sequences representing a tumour antigen 
specific target [41]. Peptide vaccinations offer the advan-
tage of high specificity and ease of antigen-generation. 
Limitations include poor immunogenicity of peptides 
which can be circumvented through conjugation to a car-
rier protein such as keyhole limpet haemocyanin (KLH) 
or tetanus toxoid [42]. Furthermore, adjuvants have been 
required because soluble antigens are generally poor at 
driving cellular immune responses. Despite identification of 
several GBM targets, including specific EGFR mutations, 
PDGFR, PTEN and IDH1, very few have been evaluated 
for vaccine production. Those assessed include Rindopep-
imut (Rintega®, CDX-110), an EGFRvIII-based vaccine 
designed to target EGFRvIII-positive GBM patients, show-
ing benefits in recurrent patients in a Phase II trial [43]. The 
results of the Phase II Study of Rindopepimut/GM-CSF in 
GBM patients (ACT III) indicated an increase in survival 
(NCT01480479) [44] however the Phase III (ACT IV) study 
was discontinued in March 2016 as the study was deemed 
unlikely to meet its overall survival endpoint with both the 
Rindopepimut and control arm performing on par with each 
other [45]. Additional trials using peptide-based vaccines in 
GBM, including those targeting IDH1 mutations, are out-
lined in Table 1 . A lack of homogenous GBM-specific anti-
gen expression is a central challenge for GBM targeting and 
NK cells express a variety of activating recept rs, includ-
ing NKp46, NKp30, and NKp44, DNAX accessory mol-
ecule-1 (DNAM-1) and natural killer group 2, m mber D 
(NKG2D); which, upon activation, trigger NK-mediated 
cytotoxicity [25 ]. Although in vitro work is pr mising, 
there is limited data to suggest that NK cells are capabl  
of traversing the blood–brain barrier with abs nce or rare 
detection in brain tumours [26]. Theref re induction of host 
immune response through alterna ive approaches such as 
vaccines or external induction of Th1-type respons  ha  been 
evaluated. LAK cells are a mixt re of lymphokine- ctivated 
CD3 + T lymphocytes and NK cells. Phase I t ial  assessed 
LAK cells as an adjunct to biphasic antibody treatment of 
advanced GBM [27 ], which was further ass ssed n 2008 
in solid tumours [28 ]. Promising Phase II trials showed, as 
an adjunct therapy, increased survival sufficiently warrants 
further evaluation in randomised tr als [29], which have ye  
to be undertaken. Similarly, Phase I intracranial and intrave-
nous NK cell injection showed tumour regression in  small 
number of patients, but with no overa l sur ival assessment 
[30]. Further trials to assess improved survival have yet o 
be conducted.
Additionally, host cells tha  have b en genetically modi-
fied with anti-tumour T cell receptors (TCRs) or chimeric 
antigen receptors (CARs) which specifically target tumour 
antigens (Fig. 1 ). TCRs on the surface of circul ting T cells 
recognise tumour MHC-presented antigens. Depending n 
the antigen presentation pathway, TCRs can recognise intra-
cellular or cross-presented ntigens (Class 1, presenting to 
CD8 + T cells) or endocytosed antigens (Class II, presenting 
to CD4+ T cells). Alternatively, CARs or CAR-modified T 
cells are engineered receptors whereby the specificity of a 
monoclonal antibody is imposed onto an isolated portion of 
the patients T cells which, now ca abl  of targeting tumour-
specific antigens, are reinfused into the patient as targeted 
therapy.
ACT therapy for GBM has evolved from th  us of 
non-specific NK and LAK cells to tumour-specific activa-
tion of the immune system, using virus specific CTLs and 
CAR-modified T cells. This approach has been investigated 
as several GBM-specific CARs have been identified [31 ] 
with current Phase I/II trials of a ti-EGFRvIII CAR-T cells 
being held in glioma (NCT02209376 and NCT01454596). 
Additional Phase I studies invo ving allogenic CTLs 
expressing genetically modified T cells targeting IL13Rα2 
(NCT01082926) and CAR modified CMV-specific cyto-
toxic lymphocytes (NCT01109095) indicate hat th s 
approach is clinically applicable, with minimal therapy 
related side effects and transient anti-glioma responses in a 
IL13Rα2-expressing GBM tumour cohort [32 , 33].
Viral immunotherapy Another form of immunotherapy 
uses live viruses to carry DNA into hum n cells, known as 
viral vector vaccines. These vectors contain DNA encoding 
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take up tumour antigens, transport them to the lymph nodes, 
presenting via MHC Class I and II to CD8+ and CD4+ T 
cells and induce a tumour-specific immune response. The 
primary challenge in vivo is addressing the optimal mecha-
nism through which DCs are activated, as effective vaccines 
should be capable of activating DCs to promote efficient 
Th1 responses and CTL [47]. As discussed previously, Th1 
responses in addition to CTL play an important role in 
anti-tumour immunity so it’s essential that active immuno-
therapy activates DCs appropriately to provide the signals 
required for promoting potent cell-mediated immunity [48]. 
In this regard, DCs can be loaded with antigen in the pres-
ence of DC stimulating factors such as toll-like receptor 
(TLR) ligands to induce DC maturation [49].
peptide vaccine development, with antigen identification 
limited to in vitro assessment. New echniques m y provide 
a means of identifying specific antigenic targets to enhance 
the endogenous immune response elicited by p ptide vac-
cination in the GBM microenvironment. F r example, Zhou 
et al. developed an in vivo scre n invol ng po led short 
hairpin RNA (shRNA) that were designed to target nega-
tive regulators of T cells. Th e targeting shRNA were then 
highly enriched in tumours by releasing a block on T lym-
phocyte proliferation upon tumour antigen r cognition [46]. 
Such techniques may prove promising for antigen identifi-
cation in further GBM vaccinations.
Dendritic cells (DCs) are key antigen presenting cel s 
(APCs) involved in the initiation of adaptive immunity. DCs 
Table 1 Peptide-based vaccines for GBM therapy, data collated from https://clinicaltrials.gov




EGFRvIII mutant targeting conjugated to keyhole limpet 
haemocyanin (KLH) carrier protein
NCT01480479 Randomised Phase III currently 
underway initial Phase III showed 
increased PFS and OS from point 
of diagnosis
HSPPC-96 An autologous heat-shock protein peptide complex-96 
(HSPPC-96) vaccine for patients with recurrent GBM
NCT01814813 Randomised Phase II single arm trial 
showed promise however lympho-
penia was noted as an adverse side 
effect
ERC1671 Whole GBM tumour cells and lysates from patient donorsNCT01903330 Phas  II results showed great prom-
ise with reduced tumour infiltration 
and no noted side effects 
SL-701 Synthetic multi-peptide immunotherapy consisting of three 
shortened peptides corresponding to IL-13, Rα2 and sur-
vivin that have been engineered with amino acid substitu-
tions to increase immunostimulatory activity
NCT02078648 Phase I/II, currently ongoing 
NeoVax Vaccine applicable to patients with MGMT-unmethylated 
status
NCT02287428 Phase I currently ongoing until Janu-
ary 2018
ADU-623 A live-attenuated, double-deleted strain of the Gram-positive 
bacterium Listeria monocytogenes (Lm) encoding EGFR-
vIII and the cancer antigen NY-ESO-1
NCT01967758 Phase I du  to comple e in April 
2017
GAPVAC Several actively personalised vaccines (APVACs) tailored to 
the characteristics of each individual patient’s tumour
NCT02149225 Phase I due to be completed in July 
2018
IMA950 Multipeptide vaccine Peptides in IMA950 comprise the 
following: brevican (BCAN); chondroitin sulfate pro-
teoglycan 4 (CSPG4); fatty acid binding protein 7, brain 
(FABP7); insulin-like growth factor 2 mRNA binding pro-
tein 3 (IGF2BP3); neuroligin 4, X-linked (NLGN4X); neu-
ronal cell adhesion molecule (NRCAM); protein tyrosine 
phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1); 
tenascin C (TNC); Met proto-oncogene (MET); baculovi-




Phase I/II completed in March 
2016 reported that IMA950 plus 
granulocyte macrophage colony-
stimulating factor (GM-CSF) was 
well tolerated with the primary 
immunogenicity endpoint of 
observing multi-tumour associ-
ated peptide responses in at 
least 30 % of pat ents exceeded. 





Per onalised peptide vaccinesNCT02510950 Pilot study Phase 0 due for comple-
tion in March 2019
IDH R132H and 
PEPIDH1M
Trials to evaluate the safety and tolerability of and immune 
response to the IDH1 peptide vaccine in patients with 
IDH1R132H-mutated, WHO grade III-IV gliomas
NCT02454634 and 
NCT02193347
Phase I rials, due for completion 
in August 2018 and June 2019, 
respectively
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in hydrogen atoms from water molecules. The intensity and 
quality of an MRI signal is determined by two characteris-
tics of the target tissue, the nuclear spin–lattice time (T1) 
and the spin–spin relaxation time (T2). Current radiographic 
assessment of GBM progression is based on T1-weighted 
(positive contrast) MRIs, however T2-weighted (negative 
contrast) imaging has been used for vasogenic oedema, 
gliosis and chemotherapy-related treatment effect visu
alisation [53], with radiographic response criteria stipu-
lated under the Response Assessment in Neuro-Oncology 
(RANO) working group [54]. T1-weighted MRI is effective 
in identification of necrotic regions of brain tissue and, quite 
often, a contrast agent may be used to enhance imaging of 
additional tissue features. Primary GBM treatment involves 
a multimodal approach including surgical resection and 
radiotherapy with concomitant and adjunct chemotherapy. 
Three months post treatment completion, approximately 
20–30 % of patients may show high contrast on MRI 
which may not indicate true disease progression, but rather 
pseudoprogression, caused by increased inflammation 
and blood brain barrier (BBB) disruption due to radiation 
and TMZ treatment [55]. As immunotherapy recruits the 
hosts immune system as a means of targeting GBM cells, 
inflammation occurs leading to the radiographic effect of 
‘lesion’ enhancement and additional ‘lesion’ detection, sug-
gestive of disease progression and premature cessation of 
immunotherapy [55]. As reviewed by Brandes et al. [56], 
In order to avoid the challe ge of identifying bro dly 
recognised tumour specific GBM antigens, DCs can be 
‘primed’ using whole tumour lysates. Such methods have 
been employed in Phase I/II trials in GBM [50] which, 
when used in combination with tandard clinical practise, 
improves patient response and urvival rate . The current 
findings from six clinical studies [51 ] shows that DC immu-
notherapy led to a significant increase in overall and 2 year 
survival rates compared to stand rd clinical protocols with 
minimal toxicity. Notably, thes  stu ies av  low cohort 
numbers, requiring further recruits before definitive con-
clusions can be drawn; however initial findings are prom-
ising with several Phase I and III clinical tri ls underway 
(Table 2 ). Recently, Mitchell et al. [52 ] showed that pre-
conditioning of a DC vaccination site with an intramuscu ar 
vaccine of Td toxoid (Sanofi Aventis; Decavac; 1 Lf, 100 μl) 
results in a significant increase in lymph node homing and 
efficacy of GBM tumour antigen primed DCs in a murine 
model of GBM. This improvement was noted in both pro-
gression free (PF) and overall survival (OS) rates.
Imaging challenges in immuno herapy
Magnetic resonance imaging (MRI) is a medical i aging 
technique which is based upon the use of strong magnetic 
fields to detect ‘spin’ in atomic nuclei, for example the spin 
Table 2 DC-based vaccines for GBM therapy, data collated from htt s://clinical rials.gov
Name Description NCT numberPhase
DCVax-L Activated monocytes loaded with antigens from the  
patient’s own tumour tissue
NCT00045968 Pha e III, September 2016, ongoing
ICT-107 NCT01280552 Promising Phase I and II trials (Phuphanich 
et al. [50], http://www.imux.com 2015), 
Phase III trials are randomised, double-
blinded, placebo-controlled to assess 
changes in overall survival
ICT-121 Specifically targets CD133 NCT02049489 Phase I, due for completion in November 
2017, http://www.imux.com
DC vaccineAutologous dendritic cells pulsed with lysate derived from 
an allogeneic glioblastoma stem-like cell line for patients 
with newly diagnosed or recurrent glioblastoma
NCT02010606 A phase I trial t sting a dendritic cell vac-
cine for patients with newly diagnosed or 
recurrent glioblastoma, due for comple-
tion in October 2018
DC vaccineTo demonstrate that dendritic cell vaccine loaded with 
tumor lysate is feasible and safe in pediatric and adult 
subjects with relapsed high grade glioma or glioblastoma 
multiforme




Evaluation of overcoming limited migration and enhancing 
cytomega ovirus-specific Dendritic Cell Vaccines with 
adjuvant tetanus pre-conditioning in patients with newly-
diagnosed GBM
NCT02366728 R nd mise  Phase II, due for completion in 
June 2020
CMV pp65 DCsAVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in 
combination with DC vaccines for the treatment of recur-
rent Grade III and Grade IV brain tumours
NCT02529072 Randomised phase I/II, due for completion 
in March 2019
1 3
J Neurooncol (2017) 131:1–96
Open Access Thi  article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://cre-
ativecommons.org/licenses/by/4.0/), which p rmits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, 
Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau 
P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, 
Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe 
D, Cairncross JG, Mirimanoff RO, European Organisation for 
Research and Treatment of Cancer Brain Trials, Radiation Oncol-
ogy Group, National Cancer Institute of Canada Clinical Trials 
Group (2009) Effects of radiotherapy with concomitant and adju-
vant temozolomide versus radiotherapy alone on survival in glio-
blastoma in a randomised phase III study: 5-year analysis of the 
EORTC-NCIC trial. Lancet Oncol 10(5):459–466. doi:10.1016/
S1470-2045(09)70025-7
 2. Yu JB, Jiang H, Zhan RY (2016) Aberrant Notch signaling in glio-
blastoma stem cells contributes to tumor recurrence and invasion. 
Mol Med Rep. doi:10.3892/mmr.2016.5391
 3. Watters JJ, Schartner JM, Badie B (2005) Microglia function 
in brain tumors. J Neurosci Res 81(3):447–455. doi:10.1002/
jnr.20485
 4. Atai NA, Bansal M, Lo C, Bosman J, Tigchelaar W, Bosch 
KS, Jonker A, De Witt Hamer PC, Troost D, McCulloch 
CA, Everts V, Van Noorden CJ, Sodek J (2011) Osteopon-
tin is up-regulated and associated with neutrophil and macro-
phage infiltration in glioblastoma. Immunology 132(1):39–48. 
doi:10.1111/j.1365-2567.2010.03335.x
 5. Cai J, Zhang W, Yang P, Wang Y, Li M, Zhang C, Wang Z, Hu 
H, Liu Y, Li Q, Wen J, Sun B, Wang X, Jiang T, Jiang C (2015) 
Identification of a 6-cytokine prognostic signature in patients 
with primary glioblastoma harboring M2 microglia/macrophage 
phenotype relevance. PloS One 10(5):e0126022. doi:10.1371/
journal.pone.0126022
 6. Singh MK, Bhattacharya D, Chaudhuri S, Acharya S, Kumar P, 
Santra P, Basu AK, Chaudhuri S (2014) T11TS inhibits glioma 
angiogenesis by modulation of MMPs, TIMPs, with related integ-
rin alphav and TGF-beta1 expressions. Tumour Biol 35(3):2231–
2246. doi:10.1007/s13277-013-1296-8
 7. Lively S, Schlichter LC (2013) The microglial activation state reg-
ulates migration and roles of matrix-dissolving enzymes for inva-
sion. J Neuroinflammation 10:75. doi:10.1186/1742-2094-10-75
 8. Herbertz S, Sawyer JS, Stauber AJ, Gueorguieva I, Driscoll KE, 
Estrem ST, Cleverly AL, Desaiah D, Guba SC, Benhadji KA, 
Slapak CA, Lahn MM (2015) Clinical development of galu-
nisertib (LY2157299 monohydrate), a small molecule inhibitor 
of transforming growth factor-beta signaling pathway. Drug Des 
Devel Ther 9:4479–4499. doi:10.2147/DDDT.S86621
 9. Han J, Alvarez-Breckenridge CA, Wang QE, Yu J (2015) TGF-
beta signaling and its targeting for glioma treatment. Am J Cancer 
Res 5(3):945–955
10. Bogdahn U, Hau P, Stockhammer G, Venkataramana NK, 
Mahapatra AK, Suri A, Balasubramaniam A, Nair S, Oliushine 
V, Parfenov V, Poverennova I, Zaaroor M, Jachimczak P, Ludwig 
S, Schmaus S, Heinrichs H, Schlingensiepen KH, Trabedersen 
Glioma Study G (2011) Targeted therapy for high-grade glioma 
with the TGF-beta2 inhibitor trabedersen: results of a randomized 
identification of true disease progression versus pseudopro-
gression is a challenging pitfall in neurooncology. Given the 
promise of clinical trials for GBM immunotherapy, estab-
lishment of immune-related-RANO (iRANO) criteria has 
been undertaken. iRANO criteria define progressive disease 
as ‘disease which persists beyond a determined period of 
time after initial radiographic evidence of progression’ sub-
sequent to immunotherapy completion [57], thereby rov d-
ing a standardised criteria to assess the beneficial effect of 
immunotherapy in cancers including GBM. In addition to 
iRANO criteria, post-treatment diagnostics can include pro-
ton MR spectroscopic imaging (1H-MRSI), detecting chem-
ical compounds and metabolites commonly detect d in 
brain tissue including choline (Cho), creatine (Cre), lactate, 
lipid, and N-acetylaspartate (NAA). A ecent study utilizing 
1H-MRSI reported a 97 % success rate in retrospective dif-
ferentiation between recurrent umour and pseudoprogres-
sion and/or radiation injury, with increased Cho/NAA and 
Cho/Cre ratios in areas of recurrent tumour, compared with 
areas of lesions and normal adjacent brain tissue [58 ]. This, 
however, is not yet standard clinical practise but may, most 
likely, be required as immunotherapy trials increase in the 
future, to determine true therapeutic potential versu  trial 
cessation.
Although immunotherapy holds great promise in terms of 
GBM treatment, the anti-tumour effect has yet to be proven 
in a translational context. Improvement in terms of over ll 
survival rates is the primary focus of novel drug therapy 
mechanisms for this aggressive form of tumour. Major chal-
lenges include not only the limited number of GBM patients 
who are eligible to join particul r clin cal studies, but also 
a deep understanding of various regulatory and s i ul to y 
factors in the immune system and tumour microenvironment 
of this highly heterogeneous tumour. Positive results from 
ongoing clinical trials in terms of survival benefit would 
ultimately result in immunotherapy b coming a s andard 
part of the clinical treatment regime, and provide o portu i-
ties for new combination therapies to be explored.
Acknowledgments AT is funded by the Irish Cancer Soc ety 
Research Fellowship CRF13TIV, supported by Tesco Charity of the 
Year. TH was funded by the ERASMUS+ program. Vaccine research 
in the Lavelle group is supported by Science Foundation Irel nd 
(SFI) under Grant Number 12/IA/1421 and the SFI Research Centre, 
Advanced Materials and BioEngineering Research (AMBER) under 
Grant Number SFI/12/RC/2278. JHMP receives support from Science 
Foundation Ireland (14/IA/2582) and Brain Tumour Ireland.
Author contributions Amanda Tivnan, Tatjana Heilinger, Ed C. 
Lavelle and Jochen H.M. Prehn contributed equally to this review.
Compliance with ethical standards
Conflict of interest The author(s) declare that they have no compet-
ing interests.
1 3
J Neurooncol (2017) 131:1–9 7
tumour-specific T cell functions. J Neuroimmunol 225(1–2):22–
33. doi:10.1016/j.jneuroim.2010.04.003
23. Sawamura Y, Hosokawa M, Kuppner MC, Kobayashi H, Aida T, 
Abe H, de Tribolet N (1989) Antitumor activity and surface pheno-
types of human glioma-infiltrating lymphocytes after in vitro expan-
sion in the presence of interleukin 2. Cancer Res 49(7):1843–1849
24. Dhodapkar KM, Cirignano B, Chamian F, Zagzag D, Miller DC, 
Finlay JL, Steinman RM (2004) Invariant natural killer T cells 
are preserved in patients with glioma and exhibit antitumor lytic 
activity following dendritic cell-mediated expansion. Int J Cancer 
109(6):893–899. doi:10.1002/ijc.20050
25. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti 
A, Griffero F, Marubbi D, Spaziante R, Bellora F, Moretta L, 
Moretta A, Corte G, Bottino C (2009) NK cells recognize and kill 
human glioblastoma cells with stem cell-like properties. J Immu-
nol 182(6):3530–3539. doi:10.4049/jimmunol.0802845
26. Stevens A, Kloter I, Roggendorf W (1988) Inflammatory infil-
trates and natural killer cell presence in human brain tumors. Can-
cer 61(4):738–743
27. Wallace PK, Romet-Lemonne JL, Chokri M, Kasper LH, Fanger 
MW, Fadul CE (2000) Production of macrophage-activated killer 
cells for targeting of glioblastoma cells with bispecific antibody 
to FcgammaRI and the epidermal growth factor receptor. Cancer 
Immunol Immunother 49(9):493–503
28. Fury MG, Lipton A, Smith KM, Winston CB, Pfister DG (2008) 
A phase-I trial of the epidermal growth factor receptor directed 
bispecific antibody MDX-447 without and with recombinant 
human granulocyte-colony stimulating factor in patients with 
advanced solid tumors. Cancer Immunol Immunother 57(2):155–
163. doi:10.1007/s00262-007-0357-5
29. Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, 
Sharp SL, DePriest MC (2009) Intralesional lymphokine-acti-
vated killer cells as adjuvant therapy for primary glioblastoma. J 
Immunother 32(9):914–919. doi:10.1097/CJI.0b013e3181b2910f
30. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T, 
Ohno T (2004) Autologous natural killer cell therapy for human 
recurrent malignant glioma. Anticancer Res 24(3b):1861–1871
31. Genssler S, Burger MC, Zhang C, Oelsner S, Mildenberger 
I, Wagner M, Steinbach JP, Wels WS (2016) Dual targeting of 
glioblastoma with chimeric antigen receptor-engineered natural 
killer cells overcomes heterogeneity of target antigen expression 
and enhances antitumor activity and survival. Oncoimmunology 
5(4):e1119354. doi:10.1080/2162402X.2015.1119354
32. Sengupta S, Thaci B, Crawford AC, Sampath P (2014) Interleu-
kin-13 receptor alpha 2-targeted glioblastoma immunotherapy. 
Biomed Res Int 2014:952128. doi:10.1155/2014/952128
33. Ahmed N, Brawley V, Hegde M, Bielamowicz K, Wakefield A, 
Ghazi A, Ashoori A, Diouf O, Gerken C, Landi D, Kalra M, Yi Z, 
Rooney CM, Dotti G, Gee A, Heslop H, Gottschalk S, Powell S, 
Grossman R, Wels WS, Kew Y, Baskin D, Zhang J, New P, Hicks 
J (2015) Autologous HER2 CMV bispecific CAR T cells are safe 
and demonstrate clinical benefit for glioblastoma in a Phase I 
trial. J Immunother Cancer 3(Suppl 2):011
34. Larocca C, Schlom J (2011) Viral vector-based therapeutic cancer 
vaccines. Cancer J (Sudbury, Mass) 17(5):359–371. doi:10.1097/
PPO.0b013e3182325e63
35. Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, 
Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo 
J (2009) Oncolytic adenovirus retargeted to Delta-EGFR induces 
selective antiglioma activity. Cancer Gene Ther 16(3):256–265. 
doi:10.1038/cgt.2008.75
36. Hoffmann D, Wildner O (2007) Comparison of herpes simplex 
virus- and conditionally replicative adenovirus-based vectors 
for glioblastoma treatment. Cancer Gene Ther 14(7):627–639. 
doi:10.1038/sj.cgt.7701055
and controlled phase IIb study. Neu oonco  13(1):132–142. 
doi:10.1093/neuonc/noq142
11. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt 
S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrenc  , Locati M, 
Mantovani A, Martinez FO, Mege JL, Mosser DM, N t l  G, 
Saeij JP, Schultze JL, Shirey KA, Sica A, Suttles J, Udalova I, van 
Ginderachter JA, Vogel SN, Wynn TA (2014) Macro h ge activa-
tion and polarization: nomenclature nd exp ri e tal guidelines. 
Immunity 41(1):14–20. doi:10.1 16/j. mmuni.2014.06.008
12. Szulzewsky F, Arora S, de Witte L, Ulas T, Markovic D, Schultze 
JL, Holland EC, Synowitz M, Wolf SA, Kettenmann H (2016) 
Human glioblastoma-associated microglia/monocytes exp ess 
a distinct RNA profile compared to human control and murine 
samples. Glia 64(8):1416–1436. doi:10.1002/glia.23014
13. Zhang M, Hutter G, Kahn SA, Azad TD, Ghola i  S, Xu CY, 
Liu J, Achrol AS, Richard C, Sommerkamp P, Schoen MK, 
McCracken MN, Majeti R, Weissman I, Mitra SS, Ch shier SH
(2016) Anti-CD47 treatment stimulates phagocytosis of gl o-
blastoma by M1 and M2 polarized macrophages and promotes 
m1 polarized macrophages in vivo. P oS On  11(4):e0153550. 
doi:10.1371/journal.pone.0153550
14. Dunn GP, Old LJ, Schreiber RD (2004) The three Es of cancer 
immunoediting. Annu Rev Immunol 22:329–360. doi:10.1146/
annurev.immunol.22.012703.104803
15. Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wessel-
ing P, Grotenhuis JA, Hoogerbrugge PM, de Vries IJ, Adema GJ 
(2009) Regulatory T cells and the PD-L1/PD-1 pathway mediate 
immune suppression in malignant human brai  tumors. Neur on-
col 11(4):394–402. doi:10.1215/15228517-2008-104
16. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, 
Archer GE, Herndon JE 2nd, Bigner DD, Dranoff G, Sampson
JH (2006) Increased regulatory T cell f action amidst a dimin-
ished CD4 compartment explains cellular mmune defects in 
patients with malignant glioma. Cancer Res 66(6):329 3302. 
doi:10.1158/0008-5472.CAN-05-3773
17. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, 
Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe 
P, Lasarte JJ, Perez-Gracia JL, Melero I, Pri to J (2013) A clini-
cal trial of CTLA-4 blockade with tremelimumab  patients 
with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 
59(1):81–88. doi:10.1016/j.jhep.2013.02.022
18. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, 
Pardoll DM, Topalian SL, Anders RA (2014) Association of PD-1, 
PD-1 ligands, and other features of the tumor immune microen-
vironment with response to anti-PD-1 therapy. Clin Cancer Res 
20(19):5064–5074. doi:10.1158/1078-0432.CCR-13-3271
19. Champiat S, Ferte C, Lebel-Binay S, Eggermont A, Soria JC 
(2014) Exomics and immunogenics: Bridging mutati nal load and 
immune checkpoints efficacy. Oncoimmunology 3(1):e27817. 
doi:10.4161/onci.27817
20. Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, H -Liesko-
van S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja 
E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, 
Ribas A, Lo RS (2016) Genomic and transc iptomic features 
of response to anti-PD-1 therapy in metastatic melanoma. Cell 
165(1):35–44. doi:10.1016/j.cell.2016.02.065
21. Pitt JM, Vetizou M, Daillere R, Robert  MP, amazaki T, Routy 
B, Lepage P, Boneca IG, Chamaillard M, Kroemer G, Zitvogel 
L (2016) Resistance mechanisms to immune-checkpoint bl ck-
ade in cancer: tumor-intrinsic and - x rinsic fact rs. Immunity
44(6):1255–1269. doi:10.1016/j.immuni.2016.06.001
22. Avril T, Saikali S, Vauleon E, Jary A, amlat A, De Tayrac M, 
Mosser J, Quillien V (2010) Distinct effects of human glio-
blastoma immunoregulatory molecules pr gr mmed cell death 
ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on 
1 3
J Neurooncol (2017) 131:1–98
50. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, 
Nuno MA, Richardson JE, Fan X, Ji J, Chu RM, Bender JG, 
Hawkins ES, Patil CG, Black KL, Yu JS (2013) Phase I trial of 
a multi-epitope-pulsed dendritic cell vaccine for patients with 
newly diagnosed glioblastoma. Cancer Immunol Immunother 
62(1):125–135. doi:10.1007/s00262-012-1319-0
51. Wang X, Zhao HY, Zhang FC, Sun Y, Xiong ZY, Jiang XB (2014) 
Dendritic cell-based vaccine for the treatment of malignant gli-
oma: a systematic review. Cancer Invest 32(9):451–457. doi:10.3
109/07357907.2014.958234
52. Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez 
L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, 
Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLen-
don RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH 
(2015) Tetanus toxoid and CCL3 improve dendritic cell vaccines 
in mice and glioblastoma patients. Nature 519(7543):366–369. 
doi:10.1038/nature14320
53. Shiroishi MS, Castellazzi G, Boxerman JL, D’Amore F, Essig 
M, Nguyen TB, Provenzale JM, Enterline DS, Anzalone N, 
Dorfler A, Rovira A, Wintermark M, Law M (2015) Principles 
of T2*-weighted dynamic susceptibility contrast MRI technique 
in brain tumor imaging. J Magn Reson Imaging 41(2):296–313. 
doi:10.1002/jmri.24648
54. Vogelbaum MA, Jost S, Aghi MK, Heimberger AB, Sampson 
JH, Wen PY, Macdonald DR, Van den Bent MJ, Chang SM 
(2012) Application of novel response/progression measures 
for surgically delivered therapies for gliomas: response assess-
ment in neuro-oncology (RANO) working group. Neurosurgery 
70(1):234–243. doi:10.1227/NEU.0b013e318223f5a7 (discus-
sion 243–234)
55. Huang RY, Neagu MR, Reardon DA, Wen PY (2015) Pitfalls in 
the neuroimaging of glioblastoma in the era of antiangiogenic 
and immuno/targeted therapy: detecting illusive disease, defining 
response. Front Neurol 6:33. doi:10.3389/fneur.2015.00033
56. Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, 
Calbucci F, Franceschi E (2008) Disease progression or pseu-
doprogression after concomitant radiochemotherapy treat-
ment: pitfalls in neurooncology. Neuro-oncol 10(3):361–367. 
doi:10.1215/15228517-2008-008
57. Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick 
W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, France-
schi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins 
R, Sampson JH, Wen PY, Reardon DA (2015) Immunotherapy 
response assessment in neuro-oncology: a report of the RANO 
working group. Lancet Oncol 16(15):e534–e542. doi:10.10 /
S1470-2045(15)00088-1
58. Weybright P, Sundgren PC, Maly P, Hassan DG, Nan B, Rohrer 
S, Junck L (2005) Differentiation between brain tumor recurrence 
and radiation injury using MR spectroscopy. Am J Roentgenol 
185(6):1471–1476. doi:10.2214/ajr.04.0933
37. Enloe BM, Jay DG (2011) Inhibition of Necl-5 (CD155/PVR) 
reduces glioblastoma dispersal and decreases MMP-2 expres-
sion and activity. J Neurooncol 102(2):225–235. doi:10.1007/
s11060-010-0323-5
38. Lang FF, Conrad C, Gomez-Manzano C, al. e Phase I clinical tr al 
of oncolytic virus Delta-24-RGD (DNX-2401  with biological 
endpoints: implications for viro-immunotherapy. In: 19th a nual 
meeting of the Society for Neuro-Oncology, Miami, FL, 2014. 
Society for Neuro-Oncology (SNO)
39. Cheema TA, Fecci PE, Ning J, Rabkin SD (2 14) Immunovi-
rotherapy for the treatment of glioblastoma. Oncoimm ology 
3(1):e27218. doi:10.4161/onci.27218
40. Mantwill K, Naumann U, Seznec J, Girbinger V, Lage H, Sur-
owiak P, Beier D, Mittelbronn M, Schlegel J, Holm PS (2013) 
YB-1 dependent oncolytic adenovirus efficiently inhibits tumor 
growth of glioma cancer stem like cells. J Trans Med 11:216. 
doi:10.1186/1479-5876-11-216
41. Swartz AM, Batich KA, Fecci PE, Sampson JH (2015) Pep-
tide vaccines for the treatment of glioblastoma. J Neurooncol 
123(3):433–440. doi:10.1007/s11060-014-1676-y
42. Broker M (2015) Potential protective immunogenicity of teta-
nus toxoid, diphtheria toxoid and Cross Reacting Material 197 
(CRM197) when used as carrier proteins in glycoconjugates. 
Hum Vaccin Immunother. doi:10.1080/21645515.2015.1086048
43. Gatson NT, Weathers SP, de Groot JF (2016) ReACT hase II 
trial: a critical evaluation of the use of rindopepimut plus bevaci-
zumab to treat EGFRvIII-positive recu rent glioblastoma. CNS. 
Oncol 5(1):11–26. doi:10.2217/cns.15.38
44. Zussman BM, Engh JA (2015) Outcomes of the ACT III study: 
rindopepimut (CDX-110) therapy for glioblastoma. Neurosur-
gery 76(6):N17. doi:10.1227/01.neu.0000465855.63458.0c
45. CellDex.com (2016) The phase 3 ACT IV study of RINTEGA 
in newly diagnosed glioblastoma (discontinued). http://www.cell-
dex.com/pipeline/rindopepimut.php. Accessed 14 Sept 2016
46. Zhou P, Shaffer DR, Alvarez Arias DA, Nak zaki Y, Pos W, Tor-
res AJ, Cremasco V, Dougan SK, Cowley GS, E pek K, Brogdon 
J, Lamb J, Turley SJ, Ploegh HL, Root DE, Love JC, Dranoff 
G, Hacohen N, Cantor H, Wucherpfennig KW (2014) In vivo 
discovery of immunotherapy targets in the tumour microenviron-
ment. Nature 506(7486):52–57. doi:10.1038/nature12988
47. Briseno CG, Haldar M, Kretzer NM, Wu X, Theisen DJ, Kc W, 
Durai V, Grajales-Reyes GE, Iwata A, Bagadia P, Murphy TL, 
Murphy KM (2016) Distinct transcription l r grams control 
cross-priming in classical and monocyte-derived dendritic cells. 
Cell Rep 15(11):2462–2474. doi:10.1016/j.celrep.2016.05.025
48. Zitvogel L, Kroemer G (2014) CD103+ dendritic cells produc-
ing interleukin-12 in anticancer immunosurveillance. Cancer cell 
26(5):591–593. doi:10.1016/j.ccell.2014.10.008
49. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, 
Ricciardi-Castagnoli P, Raposo G, Amigorena S (1998) Eradica-
tion of established murine tumors using a novel cell-free vaccine: 
dendritic cell-derived exosomes. Nat Med 4(5):594–600
1 3
J Neurooncol (2017) 131:1–9 9
